Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

18th International Meeting of the European Society of Gynaecological Oncology (ESGO) /
Outcomes of early stage ovarian endometrioid carcinoma

19th - 22nd Oct 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.10.13
Views: 5569

Dr Aalok Kumar - Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada

Dr Kumar talks to ecancer at the 2013 ESGO meeting about a study that looks at outcomes of patients with early stage ovarian endometroid carcinoma.

The aims of the study were to determine prognostic factors and determine the impact of adjuvant treatment on survival in patients with early stage ovarian endometroid carcinoma.

The study found that omission of adjuvant treatment could be considered in the majority of early stage ovarian endometroid carcinoma, except stage IC other and II, where irradiation may be of benefit.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation